Tags : Steroid-Refractory Acute Graft-Versus-Host Disease

$Mallinckrodt Reports Results of Therakos Photopheresis Therapy in P-III study for Steroid-Refractory Acute Graft-Versus-Host Disease (aGvHD)$

Pharma

Mallinckrodt Reports Results of Therakos Photopheresis Therapy in P-III study

Vartika Singh February 22, 2019

Shots: The P-III (NCT02524847) study involves assessing of Therakos + methoxsalene in 25 pediatric patients with aGvHD aged 1 yr to 21 yrs. @4,12 wks. The P-III study resulted in […]readmore

Tags : Steroid-Refractory Acute Graft-Versus-Host Disease

Mallinckrodt Reports Results of Therakos Photopheresis Therapy in P-III study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Steroid-Refractory Acute Graft-Versus-Host Disease

Mallinckrodt Reports Results of Therakos Photopheresis Therapy in P-III study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company